PNTG is the ticker symbol for Pennant Group, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks PNTG with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is PNTG a good stock to buy?

13F Pro's AI ranking engine scores PNTG at 62.6/100, ranked #697 of 2,960 stocks based on 32 fundamental signals including profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for PNTG is available at https://13fpro.ai/company/PNTG. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source PNTG data?

All Pennant Group, Inc. fundamentals and ownership data come directly from SEC EDGAR. Pennant Group, Inc. files with the SEC under CIK 1766400. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Pennant Group, Inc.(PNTG)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Pennant Group, Inc. (PNTG) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PNTG at 62.6/100 on a 32-signal composite quality model, placing it at rank #697 of 2,960 stocks — the top 25% of the AI-ranked universe. PNTG scores in the top quartile across revenue growth (90.0), institutional flow (81.1), earnings quality (78.7). Areas of concern include free cash flow (36.1), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Pennant Group, Inc. reports quarterly revenue of $298.0M, net income of $9.1M, an operating margin of 5.8%. Top institutional holders of PNTG by reported 13-F value include BlackRock, Van Berkom & Associates, WASATCH ADVISORS, based on the most recent SEC filings. PNTG trades on the Nasdaq exchange and files with the SEC under CIK 1766400. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PNTG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pennant Group, Inc. directly from SEC EDGAR.

AI Quality Score

62.6/100

AI Rank

#697

Revenue

$298.0M

Net Income

$9.1M

Free Cash Flow

$15.5M

Operating Margin

5.8%

PNTG key financials by period

Pennant Group, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	10-K	$947.7M	$29.6M	5.5%
FY 2024	10-K	$695.2M	$22.6M	5.5%
FY 2023	10-K	$544.9M	$13.4M	4.6%
FY 2022	10-K	$473.2M	$6.6M	2.7%
FY 2021	10-K	$439.7M	$2.7M	1.1%
FY 2020	10-K	$391.0M	$15.7M	4.8%

Institutions holding PNTG

Institutional investors reporting a position in Pennant Group, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
BlackRock	2,959,141	$109.3M	2026-06-30
Van Berkom & Associates	2,369,269	$87.5M	2026-06-30
WASATCH ADVISORS	1,870,178	$69.1M	2026-06-30
Turtle Creek Asset Management	1,714,462	$63.3M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	1,480,881	$54.7M	2026-06-30
PARADIGM CAPITAL MANAGEMENT	1,402,800	$51.8M	2026-06-30
FMR	1,182,138	$43.7M	2026-06-30
Provident Investment Management	939,208	$34.7M	2026-06-30
GOLDMAN SACHS GROUP	891,426	$32.9M	2026-06-30
GEODE CAPITAL MANAGEMENT	886,783	$32.8M	2026-06-30

SEC EDGAR: CIK 1766400 →

Pennant Group, Inc.

PNTG

NasdaqSmall CapHealthcare

13F Pro Quality Score

62.6/100

Rank #697 of 2,960 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

90.0/100

Profitability

41.6/100

Balance Sheet

62.8/100

Earnings Quality

78.7/100

Free Cash Flow

36.1/100

Institutional Flow

81.1/100

Revenue Scale

51.7/100

Dilution Risk

58.4/100

Price Chart

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

What's Driving PNTG's Business? Latest 10-Q Breakdown

AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Biggest Revenue Drivers

Home Health and Hospice Services$237.4M+43.2% YoY

Higher admissions (up 62.3% total, 70.7% Medicare), increased average daily hospice census (up 40.1%), and 38 new agencies added.

Senior Living Services$60.2M+12.6% YoY

Improved average monthly revenue per occupied unit (+3.9%) and eight new communities acquired.

Biggest Revenue Drivers

Total revenue: $298.0M+35.8% YoY

Home Health and Hospice Services$237.4M+43.2% YoY

Higher admissions (up 62.3% total, 70.7% Medicare), increased average daily hospice census (up 40.1%), and 38 new agencies added.

Senior Living Services$60.2M+12.6% YoY

Improved average monthly revenue per occupied unit (+3.9%) and eight new communities acquired.

Largest Expense Items

Cost of services$242.6M+36.9% YoY

Increased volume from higher admissions and census; transition costs related to acquisitions.

General and administrative expense$21.6M+22.8% YoY

Increased payroll, incentives, and related benefits across the growing operations.

Rent—cost of services$13.4M+12.6% YoY

New operating leases for acquired home health, hospice, and senior living properties.

Margins: Operating margin improved to 5.8% from 5.3% despite acquisition-related transitional headwinds and transition services costs of $2.5M. Cost of services increased 60 basis points as a percentage of revenue to 81.4%, driven by higher cost patterns at newly acquired operations, partially offset by leverage gains in existing operations.

Watch Items from the Filing

Medicare and Medicaid revenue concentration: combined 64.3% of Q2 revenue; receivables from these programs 68.9% of total AR as of June 30, 2026.
CMS six-month moratorium on new Medicare enrollment for home health and hospice effective May 13, 2026; heightened scrutiny in Arizona, California, Georgia, Nevada, Oklahoma, Texas.
Transition services costs of $2.5M in Q2 (YTD $5.3M) related to UnitedHealth/Amedisys acquisition integration; expected to continue.
Proposed CY 2027 home health payment increase of only 2.4% and hospice increase of 2.3%; proposed Medicare enrollment restrictions and retroactive revocation rules expand CMS enforcement authority.
Debt increased to $198.5M from $175.0M YTD; available liquidity $145.6M; leverage ratio requires monitoring given acquisition pace.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →